Crossref
EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025)
Value in Health · 2026-06 · 29 (6) · S139
DOI: 10.1016/j.jval.2026.03.694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Christopher Daly und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Daly, C., & Ballreich, J. (2026). EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025). Value in Health, 29(6), S139. https://doi.org/10.1016/j.jval.2026.03.694
Vancouver
Daly C, Ballreich J. EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025). Value in Health. 2026;29(6):S139. doi:10.1016/j.jval.2026.03.694
BibTeX
@article{Daly2026,
author = {Daly, Christopher and Ballreich, Jeromie},
title = {EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025)},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S139},
doi = {10.1016/j.jval.2026.03.694}
}
EUVIMED